Morganstein DL - Search Results

1

Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma.

Morganstein DL, Lai Z, Spain L, Diem S, Levine D, Mace C, Gore M, Larkin J. Morganstein DL, et al. Clin Endocrinol (Oxf). 2017 Apr;86(4):614-620. doi: 10.1111/cen.13297. Epub 2017 Jan 27. Clin Endocrinol (Oxf). 2017. PMID: 28028828

2

SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy.

Higham CE, Olsson-Brown A, Carroll P, Cooksley T, Larkin J, Lorigan P, Morganstein D, Trainer PJ; Society for Endocrinology Clinical Committee. Higham CE, et al. Endocr Connect. 2018 Jul;7(7):G1-G7. doi: 10.1530/EC-18-0068. Endocr Connect. 2018. PMID: 29930025 Free PMC article.

3

Glucocorticoid use and complications following immune checkpoint inhibitor use in melanoma.

Agarwal K, Yousaf N, Morganstein D. Agarwal K, et al. Clin Med (Lond). 2020 Mar;20(2):163-168. doi: 10.7861/clinmed.2018-0440. Clin Med (Lond). 2020. PMID: 32188652 Free PMC article.

4

Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH.

Siddiqui MS, Lai ZM, Spain L, Greener V, Turajlic S, Larkin J, Morganstein DL. Siddiqui MS, et al. Among authors: morganstein dl. J Endocrinol Invest. 2021 Jan;44(1):195-203. doi: 10.1007/s40618-020-01297-3. Epub 2020 May 24. J Endocrinol Invest. 2021. PMID: 32449093 Free PMC article.

5

Adrenal insufficiency and checkpoint inhibitors for cancer.

Morganstein DL, Larkin J. Morganstein DL, et al. Clin Med (Lond). 2020 Sep;20(5):e139. doi: 10.7861/clinmed.Let.20.5.8. Clin Med (Lond). 2020. PMID: 32934060 Free PMC article. No abstract available.

6

Pituitary enlargement following ipilimumab without long term endocrine dysfunction.

Nogueira E, Menon A, Dede A, Mitra I, Brock C, Larkin J, Morganstein D. Nogueira E, et al. Curr Probl Cancer. 2021 Dec;45(6):100710. doi: 10.1016/j.currproblcancer.2021.100710. Epub 2021 Feb 10. Curr Probl Cancer. 2021. PMID: 33622518

7

Endocrinopathies induced by immune checkpoint inhibitors: the need for clear endocrine diagnosis.

Percik R, Larkin J, Morganstein DL. Percik R, et al. Among authors: morganstein dl. Lancet Oncol. 2021 Jul;22(7):905-907. doi: 10.1016/S1470-2045(21)00305-3. Lancet Oncol. 2021. PMID: 34197741 No abstract available.

8

Hyperglycaemia following immune checkpoint inhibitor therapy-Incidence, aetiology and assessment.

Mulla K, Farag S, Moore B, Matharu S, Young K, Larkin J, Popat S, Morganstein DL. Mulla K, et al. Among authors: morganstein dl. Diabet Med. 2023 Apr;40(4):e15053. doi: 10.1111/dme.15053. Epub 2023 Feb 6. Diabet Med. 2023. PMID: 36696014

9

Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management.

Paschou SA, Dede AD, Anagnostis PG, Vryonidou A, Morganstein D, Goulis DG. Paschou SA, et al. J Clin Endocrinol Metab. 2017 Oct 1;102(10):3621-3634. doi: 10.1210/jc.2017-00042. J Clin Endocrinol Metab. 2017. PMID: 28938433 Review.

10

Immunotherapy-induced endocrinopathies: assessment, management and monitoring.

Nogueira E, Newsom-Davis T, Morganstein DL. Nogueira E, et al. Among authors: morganstein dl. Ther Adv Endocrinol Metab. 2019 Dec 25;10:2042018819896182. doi: 10.1177/2042018819896182. eCollection 2019. Ther Adv Endocrinol Metab. 2019. PMID: 31903179 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

33 results

Search Page